Anticonvulsant Use for Prophylaxis of the Pediatric Migraine

Lea S. Eiland, PharmD, BCPS; Teri Woo, PhD(c), MS, RN, CPNP; Elizabeth Farrington, PharmD, FCCP, BCPS


J Pediatr Health Care. 2007;21(6):392-395. 

In This Article


A retrospective review of gabapentin has been described in one abstract presentation (Belman, Milazo, Savatic, & Gabis, 2001). Fifteen children, ages 6 to 17 years, experienced greater than a 50% reduction in migraine frequency and duration. Three children stopped the medication because of adverse effects (dizziness and sleep disturbance) or lack of efficacy. Because this is the only published information regarding gabapentin in children, other studies are needed prior to recommending for migraine prophylaxis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.